Actual Nurtec ODT Patient
Actual Nurtec ODT Patient
One medication in a
75 mg dose
power to treat or
prevent in your
TREATING MIGRAINE ATTACKS
Once daily PRN. Take one 75 mg ODT, as needed, for acute treatment of migraine.1
Patients with a history of 9 to 14 monthly moderate or severe migraine attacks treated with rimegepant 75 mg as needed up to once per day (median usage 8 tablets/month).2
PREVENTING THE NEXT ONE
Take one 75 mg ODT every other day for preventive treatment of episodic migraine.1
90% of patients in the clinical study adhered to the every other day dosing regimen.3
A non-CGRP acute treatment should be used on days when Nurtec ODT is taken, if needed.3
Nurtec ODT is supplied in a carton containing an 8-pack1
CGRP: calcitonin gene-related peptide
Can be taken up to
once daily as needed.
No water necessary.1,*
Can be co‑administered
with oral contraceptives
Shown to both treat and
including in patients
already on a
in people with stable
or risk factors.1,7
*Up to 18 doses of Nurtec ODT can be taken per month.1
Instruct patients to only
remove Nurtec ODT
from the blister pack
immediately before use1
No titration needed1
Patients can place
Nurtec ODT on or under
their tongue and it
Patient is free to proceed after taking a single tablet of 75 mg for either acute or preventive treatment1
Nurtec ODT has
a Tmax of 1.5 hours1
For the acute indication, Nurtec ODT was evaluated in a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co-primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptoms (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; P=.001).1
For the preventive indication, Nurtec ODT 75 mg was evaluated in a multi-center, double-blind, randomized, placebo-controlled study of 695 patients (Nurtec ODT 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9-12 (-4.3 vs -3.5, P=.01).1
A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).10
References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 5. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 7. Data on File. RIM130. Biohaven Pharmaceuticals Inc. 8. Abay FB, Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303. 9. Lipton RB, Coric V, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant 75 mg orally dissolving tablet for the acute treatment of migraine: a phase 3, double-blind, randomized, placebo-controlled trial (study 303). Abstract presented at: 61st Annual Scientific Meeting of the American Headache Society; Philadelphia, PA. Session IOR05; July 11, 2019. 10. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; April 17, 2020.
< Previous Page
Next Page >
Savings & Support
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated in adults for the:
Please click here for full Prescribing Information.
Individual results may vary.
From 2-48 hours
68% of patients taking Nurtec ODT with normal functioning at 2 hours had a sustained response through 48 hours
68% (n=174/255) of patients taking Nurtec ODT vs 60% (n=105/176) of patients taking placebo
26% of patients taking Nurtec ODT 75 mg (n=174/669) experienced return to normal function from 2‑48 hours vs 15% of patients taking placebo (n=105/682); P<.0001
From 2-48 hours
71% of patients taking Nurtec ODT who achieved pain relief at 2 hours experienced sustained pain relief through 48 hours
71% (n=282/397) of patients taking Nurtec ODT vs 58% (n=172/295) of patients taking placebo
42% of patients taking Nurtec ODT 75 mg (n=282/669) experienced pain relief from 2‑48 h vs 25% of patients taking placebo (n=172/682); P<.0001
75 mg as needed -
max 1 dose q 24 hours
1 pack per 30 days or
8 tabs per 30 days
75 mg QOD for
of episodic migraine
2 packs per 30 days or
16 tabs per 30 days